Technical Scrutiny on Biotechnology Stocks -- Gilead Sciences, Sarepta Therapeutics, Dyax Corp., and Baxalta

NEW YORK, NY / ACCESSWIRE / January 21, 2016 / Park Lane Advisor has initiated coverage on the following equities: Gilead Sciences Inc. (NASDAQ: GILD), Sarepta Therapeutics Inc. (NASDAQ: SRPT), Dyax Corporation (NASDAQ: DYAX), and Baxalta Inc. (NYSE: BXLT). Free research report on Gilead Sciences can be accessed at On Wednesday, January 20, 2016, the NASDAQ Composite ended at 4,471.69, down 0.12%, the Dow Jones Industrial Average declined 1.56%, to finish the day at 15,766.74, and the S&P 500 closed at 1,859.33, down 1.17%. The losses were broad based as eight out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.

Gilead Sciences Inc.'s stock finished Wednesday's session 0.72% higher at $90.55. A total of 19.66 million shares were traded, which was much above its three months average volume of 9.75 million shares. Over the last one month and the previous three months, Gilead Sciences Inc.'s shares have declined 11.54% and 12.23%, respectively. Additionally, the stock has lost 11.71% in the past one year. The company's shares are trading below their 50-day and 200-day moving averages by 11.36% and 15.20%, respectively. Gilead Sciences Inc.'s stock traded at a PE ratio of 8.29 and has a Relative Strength Index (RSI) of 28.03. Sign up and read the free notes on GILD at:

On Wednesday, shares in Sarepta Therapeutics Inc. ended the session 1.34% lower at $13.26. The stock reported a trading volume of 3.03 million shares, above its three months average volume of 1.86 million shares. Sarepta Therapeutics Inc.'s shares have plummeted 62.99% in the last one month and 51.64% in the previous three months. However, the stock has advanced 12.66% in the last one year. The company is trading 60.19% below its 50-day moving average and 54.67% below its 200-day moving average. Moreover, shares of Sarepta Therapeutics Inc. have an RSI of 14.30. The complimentary notes on SRPT can be downloaded in PDF format at:

Dyax Corp.'s stock edged 0.05% higher, to close the day at $38.31. The stock recorded a trading volume of 13.35 million shares, much above its three months average volume of 3.23 million shares. Dyax Corp.'s shares have gained 2.30% in the last one month and 39.51% in the previous three months. Furthermore, the stock has rallied 164.02% in the past one year. The company's shares are trading 5.32% and 36.35% above their 50-day and 200-day moving averages, respectively. Additionally, Dyax Corp. has an RSI of 73.19. Register for free on Park Lane Advisor and access the latest research on DYAX at:

On Wednesday, shares in Baxalta Inc. recorded a trading volume of 8.53 million shares, higher than their three months average volume of 5.21 million shares. The stock ended the day 1.11% lower at $40.25. Shares of the company traded at a PE ratio of 23.54. Baxalta Inc.'s stock has gained 8.08% in the last one month and 21.99% in the previous three months. The company is trading above its 50-day and 200-day moving averages by 8.50% and 15.50%, respectively. Furthermore, shares of Baxalta Inc. have an RSI of 56.01. The complete research on BXLT is available for free at:

About Park Lane Advisor:

Park Lane Advisor ("PLA") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. PLA has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PLA has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the Sponsor have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the Sponsor (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.


PLA, the Author, the Reviewer and the Sponsor (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PLA nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


PLA is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia.


For any questions, inquiries, or comments reach out to us directly at:

E-mail: media (at) ParkLaneAdvisor (dot) com

SOURCE: Park Lane Advisor

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.